This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ravdin, J I Articles by Skilogiannis, J Search for Related Content PubMed PubMed Citation Articles by Ravdin, J I Articles by Skilogiannis, J

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1989 June; 33(6): 960-962

In vitro susceptibilities of Entamoeba histolytica to azithromycin, CP-63,956, erythromycin, and metronidazole.

Department of Medicine, University of Virginia School of Medicine, Charlottesville 22908.

ABSTRACT

Current therapy of Entamoeba histolytica infection requires use of multiple agents effective at different body sites, including the intestinal lumen, intestinal tissue, and liver. Azithromycin and CP-63,956, new extended-half-life macrolides which reach high levels in tissue, exhibit in vitro antiamebic activity at 18 or 48 h of incubation at concentrations comparable to that of erythromycin and slightly higher than that of metronidazole. Azithromycin and CP-63,956 have the potential to be useful therapeutic agents for all types of E. histolytica infection.

This article has been cited by other articles:

• Sharma, M. P., Ahuja, V., Kopterides, P., Hughes, M. A., Haque, R., Petri, W. A. Jr. (2003). Amebiasis. NEJM 349: 307-308 [Full Text]